Abstract
Finding medications or vaccines that may decrease the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could potentially reduce transmission in the broader population. We developed a computational model of the U.S. simulating the spread of SARS-CoV-2 and the potential clinical and economic impact of reducing the infectious period duration. Simulation experiments found that reducing the average infectious period duration could avert a median of 442,852 [treating 25% of symptomatic cases, reducing by 0.5 days, reproductive number (R0) 3.5, and starting treatment when 15% of the population has been exposed] to 44.4 million SARS-CoV-2 cases (treating 75% of all infected cases, reducing by 3.5 days, R0 2.0). With R0 2.5, reducing the average infectious period duration by 0.5 days for 25% of symptomatic cases averted 1.4 million cases and 99,398 hospitalizations; increasing to 75% of symptomatic cases averted 2.8 million cases. At $500/person, treating 25% of symptomatic cases saved $209.5 billion (societal perspective). Further reducing the average infectious period duration by 3.5 days averted 7.4 million cases (treating 25% of symptomatic cases). Expanding treatment to 75% of all infected cases, including asymptomatic infections (R0 2.5), averted 35.9 million cases and 4 million hospitalizations, saving $48.8 billion (societal perspective and starting treatment after 5% of the population has been exposed). Our study quantifies the potential effects of reducing the SARS-CoV-2 infectious period duration.
Funder
City University of New York (CUNY) Graduate School of Public Health and Health Policy
National Institute of General Medical Sciences
Agency for Healthcare Research and Quality
United States Agency for International Development
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Publisher
Public Library of Science (PLoS)
Subject
Computational Theory and Mathematics,Cellular and Molecular Neuroscience,Genetics,Molecular Biology,Ecology,Modeling and Simulation,Ecology, Evolution, Behavior and Systematics
Reference55 articles.
1. Remdesivir for the treatment of Covid-19—preliminary report;JH Beigel;New England Journal of Medicine,2020
2. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial;Y Wang;The Lancet,2020
3. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial;P Gautret;International journal of antimicrobial agents
4. Cost-utility analysis of antiviral use under pandemic influenza using a novel approach—linking pharmacology, epidemiology and heath economics;DBC Wu;Epidemiol Infect,2018
5. Herd immunity": a rough guide;P Fine;Clin Infect Dis,2011
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献